Literature DB >> 21494315

Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review).

Lena J Gamble1, Anton V Borovjagin, Qiana L Matthews.   

Abstract

The purpose of this article was to review the current strategies of targeted therapy to integrins and define the best course of future research in ovarian cancer targeting. Cell surface integrin targeting has been used as a strategy for targeted therapy of several diseases with some success. The combination of virotherapy and integrin-targeting shows promise as a method for targeting ovarian cancer. More specifically, targeting of ovarian cancer with integrin-directed adenoviruses may lead to therapy with fewer toxicities and side effects. This article offers a review of the benefits of integrin-specific targeted therapy for several diseases and proposes a unique anti-ovarian cancer strategy involving the combination of the above with virotherapy as a potential anti-ovarian cancer treatment.

Entities:  

Year:  2010        PMID： 21494315      PMCID： PMC3008561          DOI： 10.3892/etm_00000037

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN： 1792-0981            Impact factor:   2.447


  118 in total

1.  Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor.

Authors:  K Asaoka; M Tada; Y Sawamura; J Ikeda; H Abe
Journal:  J Neurosurg       Date:  2000-06       Impact factor: 5.115

2.  Purification and functional characterization of integrin alpha v beta 5. An adhesion receptor for vitronectin.

Authors:  J W Smith; D J Vestal; S V Irwin; T A Burke; D A Cheresh
Journal:  J Biol Chem       Date:  1990-07-05       Impact factor: 5.157

3.  Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types.

Authors:  T J Wickham; P W Roelvink; D E Brough; I Kovesdi
Journal:  Nat Biotechnol       Date:  1996-11       Impact factor: 54.908

4.  Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein.

Authors:  S C Stevenson; M Rollence; J Marshall-Neff; A McClelland
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

Review 5.  Integrins: a family of cell surface receptors.

Authors:  R O Hynes
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

6.  Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.

Authors:  J C Gutheil; T N Campbell; P R Pierce; J D Watkins; W D Huse; D J Bodkin; D A Cheresh
Journal:  Clin Cancer Res       Date:  2000-08       Impact factor: 12.531

7.  Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells.

Authors:  H Fechner; X Wang; H Wang; A Jansen; M Pauschinger; H Scherübl; J M Bergelson; H P Schultheiss; W Poller
Journal:  Gene Ther       Date:  2000-11       Impact factor: 5.250

8.  Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin.

Authors:  J Nip; H Shibata; D J Loskutoff; D A Cheresh; P Brodt
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

9.  Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001.

Authors:  Mehee Choi; Clifton D Fuller; Charles R Thomas; Samuel J Wang
Journal:  Gynecol Oncol       Date:  2008-03-07       Impact factor: 5.482

10.  Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization.

Authors:  T J Wickham; E J Filardo; D A Cheresh; G R Nemerow
Journal:  J Cell Biol       Date:  1994-10       Impact factor: 10.539
View more
  8 in total

1.  Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, Δ24DoubleRGD, in an ovarian cancer model.

Authors:  Lena J Gamble; Hideyo Ugai; Minghui Wang; Anton V Borovjagin; Qiana L Matthews
Journal:  J Mol Biochem       Date:  2012-02-15

2.  In vitro synergistic action of geldanamycin- and docetaxel-containing HPMA copolymer-RGDfK conjugates against ovarian cancer.

Authors:  Nate Larson; Sarah Roberts; Abhijit Ray; Brandon Buckway; Darwin L Cheney; Hamidreza Ghandehari
Journal:  Macromol Biosci       Date:  2014-09-04       Impact factor: 4.979

Review 3.  Angiogenesis in cancer: Anti-VEGF escape mechanisms.

Authors:  Gerald W Prager; Marina Poettler; Matthias Unseld; Christoph C Zielinski
Journal:  Transl Lung Cancer Res       Date:  2012-03

4.  Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies.

Authors:  Zhongyuan Tang; Weiwei Feng; Yiqing Yang; Qun Wang
Journal:  Drug Des Devel Ther       Date:  2019-09-17       Impact factor: 4.162

5.  Prostaglandins in cancer cell adhesion, migration, and invasion.

Authors:  David G Menter; Raymond N Dubois
Journal:  Int J Cell Biol       Date:  2012-02-29

6.  A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors.

Authors:  Anitra L Farrow; Binghao J Peng; Linlin Gu; Alexandre Krendelchtchikov; Qiana L Matthews
Journal:  Viruses       Date:  2016-03-10       Impact factor: 5.048

7.  Integrin β1 regulates the invasion and radioresistance of laryngeal cancer cells by targeting CD147.

Authors:  Li Li; Xiaoxia Dong; Feng Peng; Li Shen
Journal:  Cancer Cell Int       Date:  2018-06-07       Impact factor: 5.722

8.  Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma.

Authors:  Justyna Magdalena Przystal; Sajee Waramit; Md Zahidul Islam Pranjol; Wenqing Yan; Grace Chu; Aitthiphon Chongchai; Gargi Samarth; Nagore Gene Olaciregui; Ghazaleh Tabatabai; Angel Montero Carcaboso; Eric Ofori Aboagye; Keittisak Suwan; Amin Hajitou
Journal:  EMBO Mol Med       Date:  2019-04       Impact factor: 12.137
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.